Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis

This analysis describes ibrexafungerp (Brexafemme®) exposure during pregnancy among patients with live birth deliveries in the Rapid COVID Sentinel Distributed Database (SDD) and reports demographic, pregnancy, and select health characteristics of all pregnancies and those exposed to ibrexafungerp. We distributed this request to six Rapid Sentinel Data Partners on December 1, 2023. This analysis includes three reports:

• Report 1: the study period included data from June 1, 2021 to August 31, 2023
• Report 2: the study period included data from June 1, 2021 to November 30, 2022
• Report 3: the study period included data from December 1, 2022 to August 31, 2023